ArticleMedicine2025
A multiomics analysis-assisted machine learning model identifies renal hamartoma without visible fat and homogeneous clear cell renal cell carcinoma: A retrospective cohort study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preoperative differentiation between benign renal hamartoma without visible fat (RH-WVF) and malignant homogeneous clear cell renal cell carcinoma (hm-ccRCC) is radiologically challenging, often requiring biopsy or surgery. This study aimed to develop a noninvasive preoperative diagnostic model for distinguishing the two lesions. A retrospective analysis included 371 patients with RH-WVF or hm-ccRCC (confirmed by surgical specimens) from two Jingzhou hospitals (Jan 2015-Feb 2024). Patients were randomly divided into training (70%) and validation (30%) cohorts by tumor stage. Radiomics features were extracted from CT corticomedullary and parenchymal phases; urinary proteomic markers were also included. LASSO regression screened predictive features, and nomogram/decision tree models were built, evaluated via ROC curves and decision curve analysis. Eight radiomics and three urinary proteomic features were selected. The nomogram showed robust performance (all P < .05) with area under the curve (AUC) 0.889 (95% CI: 0.832-0.946) in the training cohort and 0.895 (95% CI: 0.838-0.952) in the validation cohort, outperforming the decision tree (training AUC 0.821; validation AUC 0.808). In the validation cohort, ~32% (n = 36) low-risk patients could avoid unnecessary surgery, with a 4.7% (n = 5) false negative rate. The multi-omics model integrating CT radiomics and uromics is a reliable noninvasive tool for distinguishing RH-WVF from hm-ccRCC, facilitating precise treatment and reducing unnecessary surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.